Clinical characteristics, microbiology, and outcomes of infective endocarditis in Qatar

Ahmed Zaqout1,*, Shaban Mohammed2, Maliha Thapur1, Hussam Al-Soub1, Muna A. Al-Maslamani1,3, Abdullatif Al-Khal1,3,4, Ali S. Omrani1

ABSTRACT

Background: Infective endocarditis (IE) is a serious and potentially life-threatening disease. The epidemiology, treatment options, and outcomes have changed considerably over the last two decades. The aim of the study was to describe the epidemiology, clinical characteristics, and outcomes of patients with IE in Qatar.

Methods: Patients were identified from Hamad Medical Corporation hospitals' electronic records, the national referral center for the State of Qatar. We included those aged $\geq 18$ years with Duke Criteria-based diagnosis of IE during the period from January 2015 to September 2017. Demographic and clinical data were retrieved. Descriptive statistics were performed, and logistic regression analysis was used to describe the relationship between patient characteristics and all-cause in-hospital mortality. All potentially relevant variables were included in the univariate analysis, while those with $p < 0.1$ in the univariate logistic regression model were included in the multivariate analysis. For the final model, we calculated odds ratios (OR) adjusted for each of the variables included, along with their 95% confidence intervals (95% CI). Data were analyzed using STATA software version 15 (StataCorp, College Station, Texas, USA). The study was approved by the Institutional Research Board with a waiver for informed consent.

Results: Fifty-seven cases were included, of which 70% were males. The mean age was 51 years ($\pm 16.8$ years). Eleven (19%) were associated with prosthetic valves, and 6 (11%) with implantable cardiac devices. Fever (84%), dyspnea (46%), and heart failure (37%) were the most common presentations. Only 58% of patients had known preexisting valvular heart disease...
or an intracardiac device. Skin infections (10 patients, 18%) were the most prevalent portals of infection, followed by venous catheters, recent valve surgery, and implantable cardiac devices. Staphylococci were implicated in 19 (34%) and Streptococcaeae in 9 (16%) patients, whereas 21 (37%) patients were culture negative. Left-side IE (49 patients, 86%) was predominant. Acute kidney injury (AKI) (17 patients, 30%) and heart failure (11 patients, 19%) were common complications. The majority of patients received targeted antimicrobial therapy with at least two active agents. Only 9 (16%) patients underwent surgical intervention. Fourteen (25%) patients died of any cause before hospital discharge. Logistic regression analysis identified septic shock [OR 57.8, 95% CI 2.6 – 1360.2; p < 0.01] and AKI OR 33.9, 95% CI 2.9 – 398.1; p < 0.01) as the only risk factors independently associated with in-hospital mortality. Conclusion: Staphylococcci are the most common microbiological cause of IE in Qatar. Surgical intervention is uncommon, and mortality is relatively high. Our findings suggest that efforts should be directed toward improving IE prevention strategies in high-risk patients, encouraging early microbiological investigations and improving medical and surgical management.

Keywords: infective endocarditis, Qatar, epidemiology, outcomes, microbiology, mortality

INTRODUCTION

Despite considerable progress over the past few decades, infective endocarditis (IE) continues to be associated with multiple complications, including embolic events, aortic root or myocardial abscesses, organ failure, and acute renal failure. All-cause mortality can be as high as 37%.1,2 In the developed world, IE’s epidemiology has changed over the past few decades with a shift toward older patient age, degenerative valve disease, prosthetic valves, and implantable devices replacing rheumatic heart disease as the most frequent predisposing cardiac conditions.3–5 This change can largely be explained by the general improvement in healthcare provisions in most parts of the world, leading to decreased incidence of rheumatic heart disease and improved survival in patients with chronic medical conditions. Moreover, healthcare exposure and intravascular lines have become increasingly associated with IE.6–8 However, these pattern changes have not been reported in developing countries.9 In addition, the spectrum of causative organisms has also changed over the years with Staphylococcus aureus has become increasingly more common, followed by Streptococcus viridans group, Enterococcus species, and Coagulase-negative Staphylococci.8 Gram-negative bacteria and fungi have also become more common causes of IE.10,11 This finding could be explained by the global increase of risk factors for S. aureus-associated IE, such as healthcare contact and invasive procedures. Improvements in echocardiographic imaging have resulted in better diagnostic sensitivity and specificity.12 An increasing recognition of the potential role of nuclear imaging techniques such as radiolabeled leukocyte scintigraphy and 18F-fluorodeoxyglucose positron emission tomographic computed tomographic (FDG-PET/CT) has led some guideline writing committees to include them in their diagnostic criteria for IE.13,14 Newer antimicrobial agents and approaches have become established for the treatment of some forms of IE. Examples include daptomycin for methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus species15 and ampicillin/ceftriaxone combination for the treatment of E. faecalis IE.16 The initial promise of glycopeptide/β-lactam combinations for MRSA bloodstream infections was not supported by the results of a subsequent randomized clinical trial.17,18 Successful outcomes have also been reported with ceftaroline for MRSA IE.19 Data on IE in Qatar are limited to four individual cases of infective endocarditis caused by Brucella species and a single case caused by Streptococcus pneumoniae.20,21 An abstract was presented at an international cardiology conference in the year 2014, describing a decrease in the incidence of IE over two time points. However, the abstract does not provide any clinical or microbiological details of the cases.22 We sought to investigate the epidemiology, clinical characteristics, microbiological profile, and outcomes of IE in Qatar and compare those with data reported from other countries and regions.

METHODS

Hamad Medical Corporation (HMC) is a governmental tertiary care center that provides medical and surgical care for IE in Qatar. Patients were identified from the hospitals’ electronic coding records using the Inter-
national Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM). Those aged ≥18 years and were discharged with a diagnosis of IE during the period between January 1, 2015, and September 30, 2017, were included. In concordance with current international guidelines, patients in whom the modified Duke criteria for definite or possible IE were not fulfilled were excluded.10,13 Demographic (age and gender), clinical data (comorbidities, clinical presentations, preexisting valvular disease), laboratory results, echocardiographic findings, antimicrobial therapy, surgical interventions, complications, and mortality data were retrieved. Cases were categorized as native valve, prosthetic valve, or cardiac device-related endocarditis. Acute kidney injury (AKI) was defined as an increase in serum creatinine concentration by ≥44.2 μmol/L or by ≥50% compared with baseline. Early surgery was defined as surgical intervention within two months from the diagnosis of IE. Degenerative valve disease conditions included aortic valve sclerosis or calcification, mitral annulus calcification, and chordal calcification.23,24 This study was approved by the Institutional Research Board with a waiver for informed consent.

Statistical analysis
Descriptive statistics are given as mean ± standard deviation (SD) or numbers and percentages, as appropriate. Logistic regression analysis was used to describe the relationship between patient characteristics and all-cause in-hospital mortality (any death happened before hospital discharge). All potentially relevant variables were included in the univariate analysis, while those with \( p < 0.1 \) in the univariate logistic regression model were included in the multivariate analysis. For the final model, we calculated the odds ratios (OR) adjusted for each of the variables included, along with their 95% confidence intervals (95% CI). Statistical analysis were performed using Stata software version 15 (StataCorp, College Station, Texas, USA).

RESULTS
A total of 85 patients were discharged with the IE diagnosis during the study period, of which 28 cases were excluded (20 did not fulfill the modified Duke criteria for definite or possible IE, three were younger than 18 years, and five had alternative diagnoses). Fifty-seven cases were included, of which 40 (70%) were males. The overall mean age was 51 (±16.8) years (Table 1).

Degenerative valvular disease (12 patients, 21%) was the most common underlying cardiac condition. IE involved native valves (38 patients, 70%), prosthetic valves (11 patients, 19%), or implantable cardiac devices (6 patients, 11%). Important comorbidities included diabetes mellitus (31 patients, 54%), and systemic hypertension (24 patients, 42%). Only 6 (11%) patients were on regular hemodialysis. Among those with an identifiable probable portal of entry, skin infections (10 patients, 18%) were the most prevalent. None of the cases was associated with intravenous drug use (Table 1).

Fever was a presenting symptom in the majority of patients (48 patients, 84%). Dyspnea (26 patients, 46%), heart failure (21 patients, 37%), and generalized fatigue (19 patients, 33%) were also common. Left-side IE (49 patients, 86%) was predominant. Most cases involved native valves (46 patients, 81%). IE occurred mostly on the mitral (27 patients, 47%) or aortic valves (21 patients, 39%) (Table 1).

Approximately one-third (21 patients, 37%) of cases had persistently negative blood cultures (Table 2). Staphylococci (19 patients, 53%) and Streptococci (9 patients, 25%) were the most common organisms identified when a microbiological etiology was confirmed. Nearly one-third of all staphylococcal cases were caused by methicillin-resistant \( S. aureus \) (6 patients, 32%). Only a minority of cases were caused by Gram-negative bacilli or \( C. auris \) species (Table 2).

Most patients received at least two intravenous antimicrobial agents (Table 3). Surgical intervention was performed for only a small proportion (9 patients, 16%) of patients. The most commonly observed complications were AKI (17 patients, 30%), congestive heart failure (11 patients, 19%), and septic shock (10 patients, 18%). One-quarter (14 patients, 25%) of patients died of any cause during the same hospital admission. The mean (SD) duration of hospital stay was 35 (±30.1) days. Logistic regression analysis identified septic shock [OR 57.8, 95% CI 2.6–1360.2; \( p = 0.01 \)] and AKI (OR 33.9, 95% CI 2.9–398.1; \( p < 0.01 \)) as the only risk factors independently associated with in-hospital mortality (Table 4).
The small number of cases in our study shows that IE is infrequent but not rare in Qatar. Similar to previous reports, IE in Qatar affected mostly middle-aged men with a male-to-female ratio of 2.3.4,25 The average patient age in our study (51 \( \pm \) 16.8 years) is comparable to that reported from some European countries, such as Finland and Greece (54.4 \( \pm \) 17.3, 54.4 \( \pm \) 17.1, respectively).26,27 However, it is higher than the mean age reported from other developing countries such as Oman, Tunisia, and Pakistan.9,25,28 The predominance of those older than 50 years in IE reports from developed countries is likely, at least in part, to reflect the declining incidence of rheumatic heart disease in these regions.29–33

The degenerative valvular disease was the most common predisposing cardiac condition in our population. Our observation is consistent with reports from North America, Argentina, and Europe.31–33 This observation could be explained by the increasing proportion of older adults in the general population with a subsequent rise in degenerative valvular lesions. In addition, more patients have prosthetic valves, intracardiac electronic devices, or long-term intravenous lines.2,34 More than one-third (42%) of patients with IE in our study had no previously known cardiac abnormalities. Contrary to traditional teaching, clinicians should actively consider IE in patients presenting with consistent clinical features, even in the absence of known valvular disease or prosthetic cardiac devices.27,34–36

Table 1. Baseline characteristics of 57 patients with IE in Qatar

| Variable                          | Number (%) |
|-----------------------------------|------------|
| **Demographics**                  |            |
| Male gender                       | 40 (70%)   |
| Age in years (mean \( \pm \) SD)  | 51 (\( \pm \) 16.8) |
| **Underlying Cardiac condition**  |            |
| Degenerative valvular disease     | 12 (21%)   |
| Prosthetic valves                 | 11 (19%)   |
| Intracardiac device               | 8 (14%)    |
| Bicuspid aortic valve             | 1 (2%)     |
| Congenital heart disease          | 1 (2%)     |
| No previously known underlying heart disease | 24 (42%) |
| **Underlying comorbidities**      |            |
| Hypertension                      | 24 (42%)   |
| Diabetes mellitus                 | 31 (54%)   |
| Chronic kidney disease            | 11 (19%)   |
| Hemodialysis                      | 6 (11%)    |
| **Suspected port of infection**   |            |
| Dental procedures                 | 3 (5%)     |
| Intravenous catheters             | 6 (11%)    |
| Valve surgery within \( \leq \) 2 months | 6 (11%) |
| Pacemaker/implantable cardiac device | 6 (11%) |
| Skin and soft tissue infection    | 10 (18%)   |
| Intravenous drug use              | 0          |
| **Clinical Presentation**         |            |
| Fever                             | 48 (84%)   |
| Dyspnea                           | 26 (46%)   |
| Heart failure                     | 21 (37%)   |
| Fatigue                           | 19 (33%)   |
| Stroke                            | 5 (9%)     |
| Chest pain                        | 6 (10%)    |
| Shock                             | 2 (4%)     |
| Cardiac arrest                    | 1 (2%)     |
| Polyarthralgia                    | 2 (4%)     |
| **Valvular involvement**          |            |
| Aortic valve                      | 21 (37%)   |
| Mitral valve                      | 27 (47%)   |
| Aortic and mitral valves          | 1 (2%)     |
| Tricuspid valve                   | 1 (2%)     |
| Undefined                         | 7 (12%)    |
Among the clinical presentations, fever was the most prevalent symptom in our patients (84%), similar to findings from other studies. Native-valve IE (81%) and left-side IE (86%) were predominant in our study, with the mitral valve being the most commonly involved (47%) followed by the aortic valve (37%). Several studies showed similar findings. On the other hand, others showed a predominance of the aortic valve. There is no obvious explanation for this pattern of valve involvement. It could be explained, in part, by very low rates of intravenous drug abusers, central vascular catheters, and implantable cardiac devices in our cohort, which are known risk factors for right-sided infective endocarditis. Staphylococcus species, especially S. aureus, were the most prevalent causative microorganism in our study (25%), followed by the Streptococcus Viridans Group in (14%) of cases. This pattern has been reported in recent studies. Other studies still report the predominance of streptococci. MRSA were isolated from 6 (11%) cases reported here. This is higher than those reported from countries with low MRSA rates, where the proportion of IE caused by these organisms ranged between 3.7% and 7%, but it is considerably lower than rates reported from countries such as the United States where rates as high as 17.5% were recently reported. The differences in microbiological profiles of IE in different parts of the world is not surprising as it’s by large a reflection of background microbiological trends, antimicrobial resistance rates, and antimicrobial prescribing patterns.

A notable finding in our study was the high frequency of culture-negative IE (37%). Previous studies from developing countries showed comparable proportions. In contrast, in other series from developed countries, cultures were negative in only 5% to 15% of IE cases. Two most likely explanations for such a high rate of negative cultures in our series are widespread early empiric antibiotics therapy and limited access to specialized culture, serological, and molecular techniques to identify important fastidious microorganisms, such as Coxiella burnetii, Bartonella species, and others.

In line with data from other parts of the world, major complications observed in our population were AKI, heart failure, embolic stroke, and septic shock. The in-hospital mortality rate was 25%.

Table 2. Microbiology, management, complications, and outcomes of IE in Qatar

| Variable               | Number (%) |
|------------------------|------------|
| **Microbiology**       |            |
| Staphylococcus species | 19 (34%)   |
| Methicillin-sensitive S. aureus | 8 (14%)   |
| Methicillin-resistant S. aureus | 6 (11%)   |
| Coagulase-negative staphylococci | 5 (9%)    |
| Streptococcaceae       |            |
| Viridans Streptococci  | 9 (16%)    |
| S. pneumoniae          | 8 (14%)    |
| Others                 |            |
| Enterococcus faecalis  | 1 (2%)     |
| Enterococcus gallinarum| 1 (2%)     |
| Pseudomonas aeruginosa | 1 (2%)     |
| Klebsiella species     | 1 (2%)     |
| Serratia marcescens    | 1 (2%)     |
| Pandoraea species      | 1 (2%)     |
| Bacteroides fragilis   | 1 (2%)     |
| Candida parapsilosis   | 1 (2%)     |
| Culture negative       | 21 (37%)   |
| **Mode of Treatment**  |            |
| Medical only           | 48 (84%)   |
| Medical and surgical   | 9 (16%)    |
| **Complication**       |            |
| Acute kidney injury    | 17 (30%)   |
| Heart failure          | 11 (19%)   |
| Embolic stroke         | 4 (7%)     |
| Septic shock           | 10 (18%)   |
| **Outcomes**           |            |
| In-hospital Mortality  | 14 (25%)   |
| Length of hospital stay (± SD) | 35 (± 30.1) |
congestive heart failure, and septic shock. AKI is a well-recognized independent risk factor for short- and long-term mortality in patients with or without acute IE. These findings could be explained by the high rate of heart failure with concomitant use of nephrotoxic diuretics and the use of inotropic support in our cohort. Moreover, the most common organisms are *S. aureus* and *Streptococcus* species, which are associated with increased risk of IE-associated glomerulonephritis.

In our patients, the in-hospital mortality was 25%, which is within the mortality rate range of 15%–30% reported in other case series. Although, this rate is higher than rates reported in other studies. Only 9 (16%) patients in our cohort underwent early surgical intervention. Notably, out of 11 who died during the same hospitalization, only 4 (36%) had undergone surgical intervention. In general, 25%–50% of patients with acute IE may require surgical intervention during acute infection. Though potentially lifesaving in many cases, surgical intervention in this setting can be technically challenging and may lead to serious complications, especially in severely ill patients with multiple organ dysfunctions.

The risks and benefits of surgery need to be considered carefully on a case-by-case basis. Decisions on whether to proceed with surgery and the best timing should be based on multidisciplinary discussions that involve patients or their representatives.

Several studies identified an association between *S. aureus* bacteremia and higher mortality in IE. We did not find an association between any specific microorganism and all-cause mortality [unadjusted OR 1.73, 95% CI 0.49–5.99; \( p = 0.39 \)]. This might be due to the relatively small number of cases and the retrospective nature of our study. The average length of hospital stay of 30 days reported here has obvious cost and resource implications. Interventions, such as outpatient parenteral therapy or an early switch to oral antimicrobial therapy, might help to reduce the economic burden and improve patient experience.

### Table 3. Management of 57 cases of IE from Qatar according to their microbiological etiology

| Microbiological Etiology (number) | Native or Prosthetic Device* IE (number) | Definitive Antimicrobial Regimen (number) | Surgical Intervention (number, percentage) | In-hospital mortality (number, percentage) |
|----------------------------------|----------------------------------------|------------------------------------------|-------------------------------------------|--------------------------------------------|
| MSSA (8)                         | Native valve (5)                        | cloxacillin (5)                          | 1                                         | 2                                         |
|                                  | Prosthetic device (3)                   | cloxacillin plus rifampicin (3)          | 0                                         | 1                                         |
| MRSA (6)                         | Native valve (3)                        | vancomycin or daptomycin (3)             | 0                                         | 1                                         |
|                                  | Prosthetic device (3)                   | vancomycin or daptomycin, plus rifampicin (3) | 0                                         | 2                                         |
| Coagulase-Negative Staphylococci (5) | Native valve (1)                        | Daptomycin (1)                           | 0                                         | 0                                         |
|                                  | Prosthetic device (4)                   | vancomycin or daptomycin, plus rifampicin (4) | 0                                         | 1                                         |
| Streptococcus viridans (8)       | Native valve (8)                        | Ceftriaxone (8)                          | 0                                         | 0                                         |
|                                  | Prosthetic device (0)                   |                                          |                                           |                                           |
| Negative cultures (21)           | Native valve (19)                       | Ceftriaxone plus vancomycin (19)         | 6 (29%)                                   | 2 (11%)                                   |
|                                  | Prosthetic device (2)                   | Ceftriaxone plus daptomycin (2)          | 0                                         | 0                                         |
| Others (8)                       | Native valve (4)                        | Meropenem plus gentamicin (4)            | 2                                         | 1                                         |
|                                  | Prosthetic device (4)                   | Meropenem plus gentamicin (3)            | 0                                         | 1                                         |
|                                  |                                       | Fluconazole (1)                          |                                           |                                           |

*Involving prosthetic valves or intracardiac devices.

IE, infective endocarditis; MSSA, methicillin-susceptible *S. aureus*; MRSA, methicillin-resistant *S. aureus*
Our study is limited by its relatively small sample size and its retrospective nature. However, to the best of our knowledge, it is the first such study from Qatar and is larger than many studies reported from the region.

In summary, IE is an uncommon but important clinical problem in Qatar. Skin infections are an important risk for IE in Qatar. A considerable proportion of patients with IE have no known preexisting cardiac conditions. Staphylococci are the most frequently confirmed bacterial etiology of IE in Qatar, but nearly one-third of cases are culture negative. Only a small proportion of patients with IE undergo surgical intervention, and the overall mortality is high. These findings suggest that efforts should be directed toward improving IE prevention strategies in high-risk patients, encouraging early microbiological investigations and improving medical and surgical management.

**Conflict of interest**
No conflict of interest to declare.

**Ethical issues**
The study was approved by the Research Committee and Medical Research Centre at the Hamad Medical Corporation.

**Sponsor, funding**
None

**REFERENCES**

1. Cresti A, Chiavarelli M, Scalese M, Nencioni C, Valentini S, Guerrini F, et al. Epidemiological and mortality trends in infective endocarditis, a 17-year population-based prospective study. *Cardiovasc Diagn Ther.* 2017 Feb;7 (1):27 – 35.

2. Joffre J, Dumas G, Aegerter P, Dubée V, Bigé N, Preda G, et al. Epidemiology of infective endocarditis in French intensive care units over the 1997 – 2014 period-from CUB-Réa Network. *Crit Care Lond Engl.* 2019 Apr 25;23(1):143.
3. Fefer P, Raveh D, Rudensky B, Schlesinger Y, Yinnon AM. Changing epidemiology of infective endocarditis: a retrospective survey of 108 cases, 1990–1999. *Eur J Clin Microbiol Infect Dis Off Publ Eur Soc Clin Microbiol.* 2002 Jun;21(6):432–7.

4. Murdoch DR. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: The International Collaboration on Endocarditis – Prospective Cohort Study. *Arch Intern Med.* 2009 Mar 9;169(5):463.

5. Zaqout et al.

6. Fernández-Hidalgo N, Almirante B, Gavaldà J, Gurgui M, Peña C, de Alarcón A, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. *Clin Infect Dis.* 2013 May 1;56(9):1261–8.

7. Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. *JAMA.* 2020 Feb 11;323(6):527–37.

8. Davis JS, Sud A, O’Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of Vancomycin and β-Lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2016 Jan 15;62(2):173–80.

9. Tariq M, Alam M, Munir G, Khan MA, Smego RA. Infective endocarditis: a five-year experience at a tertiary care hospital in Pakistan. *Int J Infect Dis.* 2004 May;8(3):163–70.

10. Baddour LM, Wilson WR, Bayer AS, Fowler VG, Tleyjeh IM, Rybak MJ, et al. Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications. *Circulation.* 2015 Oct 13;132 (15):1435–86.

11. Pant S, Patel NJ, Deshmukh A, Golwala H, Patel N, Badheka A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *J Am Coll Cardiol.* 2015 May;65(19):2070–6.

12. Vilacosta I, Olmos C, Agustín A de, López J, Islas F, Sarriá C, et al. The diagnostic ability of echocardiography for infective endocarditis and its associated complications. *Expert Rev Cardiovasc Ther.* 2015 Nov 2;13(11):1225–36.

13. Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta J-P, Del Zotti F, et al. 2015 ESC Guidelines for the management of infective endocarditis. The task force for the management of infective endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). *Eur Heart J.* 2015 Nov 21;36 (44):3075–128.

14. Van Riet J, Hill EE, Gheyens O, Dymarkowski S, Herregods M–C, Herijgers P, et al. (18)F–FDG PET/CT for early detection of embolism and metastatic infection in patients with infective endocarditis. *Eur J Nucl Med Mol Imaging.* 2010 Jun;37(6):1189–97.

15. Fowler VG, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. *N Engl J Med.* 2006 Aug 17;355(7):653–65.

16. Fernández-Hidalgo N, Almirante B, Gavaldà J, Gurgui M, Peña C, de Alarcón A, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. *Clin Infect Dis.* 2013 May 1;56(9):1261–8.

17. Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal β-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. *JAMA.* 2020 Feb 11;323(6):527–37.

18. Davis JS, Sud A, O’Sullivan MVN, Robinson JO, Ferguson PE, Foo H, et al. Combination of Vancomycin and β-Lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. *Clin Infect Dis Off Publ Infect Dis Soc Am.* 2016 Jan 15;62(2):173–80.

19. Ho TT, Cadena J, Childs LM, Gonzalez–Velez M, Lewis JS. Methicillin-resistant Staphylococcus aureus bacteremia and endocarditis treated with ceftriaxone salvage therapy. *J Antimicrob Chemother.* 2012 May 1;67(5):1267–70.

20. Alsoub H. Brucella infective endocarditis: a report of four successfully treated patients. *Clin Microbiol Infect.* 2001;7(7):382–5.

21. Al Suob H, Saif AS. Infective endocarditis due to streptococcus pneumonia. *Qatar Med J.* 2003 Jun;2003(1):17.

22. Alam AMF, Albinai H, Singh R, Al-Qahtani A, Al Suwaidi J. Incidence of infective endocarditis before and after the 2007 endocarditis prevention guidelines: a population-based study from Qatar (2002–2012). *European Heart Journal.* 2014;35:908.

23. McKinsey DS, Ratts TE, Bisno AL. Underlying cardiac lesions in adults with infective endocarditis: the changing spectrum. *Am J Med.* 1987 Apr 1;82 (4):681–8.

24. Prasad Y, Bhalodkar NC. Aortic sclerosis—a marker of coronary atherosclerosis. *Clin Cardiol.* 2004 Dec;27 (12):671–3.

25. Al Abri SS, Zahedi FI, Kurup PJ, Al–Jardani AK, Beeching NJ. The epidemiology and outcomes of infective
endocarditis in a tertiary care hospital in Oman. J Infect Public Health. 2014 Sep;7(5):400 – 6.

26. Heiro M. Infective endocarditis in a Finnish teaching hospital: a study on 326 episodes treated during 1980 – 2004. Heart. 2006 May 15;92(10):1457 – 62.

27. Loupa C, Mavroidi N, Boutsikakis I, Paniara O, Deligiarou O, Manoli H, et al. Infective endocarditis in Greece: a changing profile. Epidemiological, microbiological and therapeutic data. Clin Microbiol Infect. 2004 Jun;10 (6):556 – 61.

28. Letaief A, Boughzala E, Kaabia N, Ernez S, Abid F, Chaabane TB, et al. Epidemiology of infective endocarditis in Tunisia: a 10-year multicenter retrospective study. Int J Infect Dis. 2007 Sep;11(5):430 – 3.

29. Cabell CH, Jollis JG, Corey GR, Anderson DJ, Sexton DJ, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 2002 Jan 14;162(1):90 – 4.

30. Hoen B, Alla F, Selton-Suty C, Béguinot I, Bouvet A, Briançon S, et al. Changing profile of infective endocarditis: results of a 1-year survey in France. JAMA. 2002 Jul 3;288(1):75

31. Toyoda N, Chikwe J, Itagaki S, Gelins AC, Adams DH, Egorova NN. Trends in infective endocarditis in California and New York State, 1998 – 2013. JAMA. 2017 Apr 25;317(16):1652.

32. Cetinkaya Y, Akova M, Akalin HE, Alçiöğlu S, Hayran M, Uzuns O, et al. A retrospective review of 228 episodes of infective endocarditis wherein rheumatic valvular disease is still common. Int J Antimicrob Agents. 2001 Jul;18(1):1 – 7.

33. Watkins DA, Johnson CO, Colquhoun SM, Karthikeyan G, Beaton A, Bukhman G, et al. global, regional, and national burden of rheumatic heart disease, 1990 – 2015. N Engl J Med. 2017 24;377(8):713 – 22.

34. Correa de Sa DD, Tleyjeh IM, Anavekar NS, Schultz JC, Thomas JM, Lahr BD, et al. Epidemiological trends of infective endocarditis: a population–based study in Olmsted County, Minnesota. Mayo Clin Proc. 2010 May;85(5):422 – 6.

35. Castillo JC, Anguita MP, Ruiz M, Peña L, Santisteban M, Puentes M, et al. Changing epidemiology of native valve infective endocarditis. Rev Esp Cardiol Eng Ed. 2011 Jul;64(7):594 – 8.

36. Juson ADS, Delgado J. The clinical profile of native-valve infective endocarditis in a tertiary hospital in the Philippines: a twelve-year retrospective study. Int J Infect Dis. 2019 Feb 1;79:47 – 8.

37. Poesen K, Pottel H, Colaert J, Niel CDe. Epidemiology of infective endocarditis in a large Belgian non-referral hospital. Acta Clin Belg. 2014 Jun;69(3):183 – 90.

38. Assiri AS. Clinical and microbiological profiles of infective endocarditis in a tertiary hospital in Aseer region, Saudi Arabia. J Saudi Heart Assoc. 2011 Oct;23(4):207 – 11.

39. Rasmussen RV, Host U, Arpi M, Hassager C, Johansen HK, Korup E, et al. Prevalence of infective endocarditis in patients with Staphylococcus aureus bacteremia: the value of screening with echocardiography. Eur J Echocardiogr. 2011 Jun 1;12(6):414 – 20.

40. Hoen B, Duval X. Infective endocarditis. N Engl J Med. 2013 Apr 11;368(15):1425 – 33.

41. Ambrosini PN, Azar V, Fantoni NS, Michaan MG, Lozano JP, Scala SL, et al. Infective endocarditis: a clinical analysis of 68 cases at a referral hospital. Int J Infect Dis. 2018 Aug 1;73:146.

42. Chahoud J, Sharif Yakan A, Saad H, Kanj SS. Right-Sided Infective Endocarditis and Pulmonary infiltrates: an update. Cardiol Rev. 2016 Oct;24(5):230 – 7.

43. Mostaghim AS, Lo HYA, Khordori N. A retrospective epidemiologic study to define risk factors, microbiology, and clinical outcomes of infective endocarditis in a large tertiary-care teaching hospital. SAGE Open Med. 2017 Dec;5:205031211774177.

44. Ambrosioni J, Hernandez-Meneses M, Téllez A, Pericás J, Falces C, Tolosana JM, et al. The changing epidemiology of infective endocarditis in the twenty-first century. Curr Infect Dis Rep. 2017 May;19(5):21.

45. Ba DM, Mboup MC, Zeba N, Dia K, Fall AN, Fall F, et al. Infective endocarditis in Principal Hospital of Dakar: a retrospective study of 42 cases over 10 years. Pan Afr Med J. 2017;26.

46. Voğkou CT, Vlachogiannis NI, Palaiodimos L, Kousoulis AA. The causative agents in infective endocarditis: a systematic review comprising 33,214 cases. Eur J Clin Microbiol Infect Dis. 2016 Aug;35(8):1227 – 45.

47. Xu H, Cai S, Dai H. Characteristics of infective endocarditis in a tertiary hospital in East China. Xu P, editor. PLOS ONE. 2016 Nov 18;11(11):e0166764.

48. Al-Tawfiq JA, Sufi I. Infective endocarditis at a hospital in Saudi Arabia: epidemiology, bacterial pathogens and outcome. Ann Saudi Med. 2009;29(6):433 – 6.

49. Nakatani S, Mitsutake K, Ohara T, Kokubo Y, Yamamoto H, Hanai S, et al. Recent picture of infective endocarditis in Japan. Circ J. 2013;77(6):1558 – 64.

50. Marks DJB, Hyams C, Koo CY, Pavlou M, Robbins J, Koo D, Sexton DJ, et al. Changing patient characteristics and the effect on mortality in endocarditis. Arch Intern Med. 2002 Jan 14;162(1):90 – 4.

51. Fournier P-E, Gouriet F, Casalta J-P, Lepidi H, Chaudet H, Thuny F, et al. Blood culture-negative endocarditis. Medicine (Baltimore). 2017 Nov 27;96(47).
52. Houpikian P, Raoult D. Blood culture-negative endocarditis in a reference center: etiologic diagnosis of 348 cases. *Medicine (Baltimore)*. 2005 May;84(3):162–73.

53. Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. *Clin Microbiol Rev.* 2001 Jan;14(1):177–207.

54. Butt AA, Navasero CS, Thomas B, Marri SA, Katheeri HA, Thani AA, et al. Antibiotic prescription patterns for upper respiratory tract infections in the outpatient Qatari population in the private sector. *Int J Infect Dis IJID Off Publ Int Soc Infect Dis.* 2017 Feb;55:20–3.

55. Ferreiros E, Nacinovich F, Casabé JH, Modenesi JC, Swieszkowski S, Cortes C, et al. Epidemiologic, clinical, and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina – 2 (EIRA-2) Study. *Am Heart J.* 2006 Feb;151(2):545–52.

56. Leone S, Ravasio V, Durante-Mangoni E, Crapis M, Carosi G, Scotton PG, et al. Epidemiology, characteristics, and outcome of infective endocarditis in Italy: the Italian Study on Endocarditis. *Infection.* 2012 Oct;40(5):527–35.

57. Ortiz-Soriano V, Donaldson K, Du G, Li Y, Lambert J, Rudy M, et al. Incidence and cost of acute kidney injury in hospitalized patients with infective endocarditis. *J Clin Med.* 2019 Jun 27;8(7).

58. Fortrie G, de Geus HRH, Betjies MGH. The aftermath of acute kidney injury: a narrative review of long-term mortality and renal function. *Crit Care.* 2019 Jan 24;23(1):24.

59. Boils CL, Nasr SH, Walker PD, Couser WG, Larsen CP. Update on endocarditis-associated glomerulonephritis. *Kidney Int.* 2015 Jun;87(6):1241–9.

60. Durante-Mangoni E, Bradley S, Selton-Suty C, Tripodi M-F, Barsic B, Bouza E, et al. Current features of infective endocarditis in elderly patients: results of the International Collaboration on Endocarditis Prospective Cohort Study. *Arch Intern Med.* 2008 Oct 27;168(19):2095–103.

61. Wang A, Athan E, Pappas PA, Fowler VG, Olaison L, Paré C, et al. Contemporary clinical profile and outcome of prosthetic valve endocarditis. *JAMA.* 2007 Mar 28;297(12):1354–61.

62. Pettersson GB, Coselli JS, Hussain ST, Griffin B, Blackstone EH, Gordon SM. AATS Surgical Treatment of Infective Endocarditis Consensus Guidelines Writing Committee. 2016 The American Association for Thoracic Surgery (AATS) consensus guidelines: Surgical treatment of infective endocarditis: executive summary. *J Thorac Cardiovasc Surg.* 2017;153(6):1241–1258.

63. Hill EE, Vanderschueren S, Verhaeghen J, Herijgers P, Claus P, Herregods M-C, et al. Risk factors for infective endocarditis and outcome of patients with Staphylococcus aureus bacteremia. *Mayo Clin Proc.* 2007 Oct;82(10):1165–9.

64. Iversen K, Ihlemann N, Gill SU, Madsen T, Elming H, Jensen KT, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. *N Engl J Med.* 2019 Jan 31;380(5):415–24.